Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial Meeting Abstract
| Authors: | Motzer, R. J.; Russo, P.; Gruenwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O. A.; Buti, S.; Barthelemy, P.; Goh, J. C. H.; Ye, D.; Lingua, A.; Lattouf, J. B.; Escudier, B.; George, S.; Shuch, B.; Simsek, B.; Spiridigliozzi, J.; Chudnovsky, A.; Bex, A. |
| Abstract Title: | Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1430 |
| Language: | English |
| ACCESSION: | WOS:000866211602479 |
| DOI: | 10.1016/j.annonc.2022.08.069 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA4 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
